LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VERA stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rami Katkhuda has given his Buy rating due to a combination of factors related to the recent updates in the 2025 KDIGO guidelines for the management of IgA nephropathy (IgAN). The guidelines now advocate for a more proactive approach in diagnosing IgAN through kidney biopsies, which could lead to earlier detection and treatment. This change is significant as it expands the treatable patient population, potentially increasing the demand for therapies that target IgAN.
Furthermore, the guidelines highlight the importance of stricter proteinuria targets, which are crucial in slowing the decline of kidney function in IgAN patients. By recommending therapies that reduce pathogenic Gd-IgA1, such as BLyS and/or APRIL inhibitors, the guidelines position these treatments as foundational options. This reinforces the potential market growth for companies like Vera Therapeutics, which is developing therapies in this area, thus supporting the Buy rating.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 30.7% and a 53.33% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Eledon Pharmaceuticals, and Dianthus Therapeutics.
In another report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $100.00 price target.